Kin­nate lays off 70% of em­ploy­ees, shaves pipeline to fo­cus on CDK4 and pan-RAF in­hibitor

Kin­nate Bio­phar­ma has re­duced its em­ploy­ee head­count by 70% — leav­ing just 28 full-time em­ploy­ees — and is “sep­a­rat­ing” from all em­ploy­ees at its Chi­nese sub­sidiary, Kin­njiu Bio­phar­ma, as part of cost-sav­ing mea­sures to ex­tend its cash run­way in­to at least the sec­ond quar­ter of 2026.

The Cal­i­for­nia-head­quar­tered can­cer com­pa­ny is al­so chang­ing up its pipeline, fo­cus­ing on its exarafenib/binime­tinib com­bo, KIN-8741, and its CDK4 se­lec­tive pro­gram. For now, Kin­nate will halt de­vel­op­ment of MEK in­hibitor KIN-7136, and “ex­plore strate­gic al­ter­na­tives” for its exarafenib monother­a­py and FGFR in­hibitor KIN-3248.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER